3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
14
Colorectal Neoplasms
3
Neoplasm Metastasis
2
Endometrial Neoplasms
2
Triple Negative Breast Neoplasms
1
Solid Tumors
1
PIK3CA-Mutated Cancers
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Metastatic Castration-Resistant Prostate Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
enzalutamide
4
Docetaxel
3
abiraterone
2
Prednisone
2
Abiraterone Acetate
2
relugolix
1
pembrolizumab
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
apalutamide
1
PF06821497
1
Methylprednisolone
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-Resistant Prostate Cancer
×
inavolisib
×
1 year
×
Clear all
NCT07287150
2026-06-04
InavoPC
Hoffmann-La Roche
Phase 2
Recruiting
100 enrolled